Athersys Current Ratio 2006-2021 | ATHX

Athersys current ratio from 2006 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Athersys Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.06B $0.03B 2.10
2021-03-31 $0.07B $0.03B 2.41
2020-12-31 $0.06B $0.02B 2.38
2020-09-30 $0.06B $0.02B 3.32
2020-06-30 $0.08B $0.02B 4.85
2020-03-31 $0.03B $0.02B 2.36
2019-12-31 $0.04B $0.01B 2.90
2019-09-30 $0.04B $0.02B 2.86
2019-06-30 $0.05B $0.02B 3.28
2019-03-31 $0.05B $0.02B 3.05
2018-12-31 $0.06B $0.02B 3.74
2018-09-30 $0.06B $0.01B 4.56
2018-06-30 $0.07B $0.02B 4.73
2018-03-31 $0.06B $0.01B 5.05
2017-12-31 $0.03B $0.01B 3.09
2017-09-30 $0.03B $0.01B 4.71
2017-06-30 $0.03B $0.01B 4.49
2017-03-31 $0.04B $0.01B 4.15
2016-12-31 $0.02B $0.01B 2.37
2016-09-30 $0.02B $0.01B 3.98
2016-06-30 $0.03B $0.01B 4.47
2016-03-31 $0.03B $0.01B 6.68
2015-12-31 $0.02B $0.01B 5.01
2015-09-30 $0.03B $0.01B 2.05
2015-06-30 $0.04B $0.01B 2.50
2015-03-31 $0.04B $0.01B 2.74
2014-12-31 $0.03B $0.01B 5.81
2014-09-30 $0.03B $0.01B 7.03
2014-06-30 $0.04B $0.00B 8.85
2014-03-31 $0.05B $0.00B 10.83
2013-12-31 $0.03B $0.00B 7.52
2013-09-30 $0.02B $0.00B 5.18
2013-06-30 $0.02B $0.01B 4.35
2013-03-31 $0.02B $0.01B 4.44
2012-12-31 $0.03B $0.00B 5.88
2012-09-30 $0.01B $0.00B 2.02
2012-06-30 $0.01B $0.00B 2.88
2012-03-31 $0.02B $0.01B 2.91
2011-12-31 $0.01B $0.01B 1.95
2011-09-30 $0.02B $0.01B 2.44
2011-06-30 $0.02B $0.01B 2.61
2011-03-31 $0.03B $0.01B 3.05
2010-12-31 $0.02B $0.01B 2.03
2010-09-30 $0.02B $0.01B 2.09
2010-06-30 $0.01B $0.01B 2.36
2010-03-31 $0.01B $0.01B 2.97
2009-12-31 $0.02B $0.01B 3.78
2009-09-30 $0.02B $0.00B 11.97
2009-06-30 $0.02B $0.00B 11.47
2009-03-31 $0.02B $0.00B 10.46
2008-12-31 $0.03B $0.00B 12.58
2008-09-30 $0.04B $0.00B 11.72
2008-06-30 $0.04B $0.00B 12.18
2008-03-31 $0.04B $0.00B 10.55
2007-12-31 $0.04B $0.01B 8.15
2007-09-30 $0.06B $0.01B 10.64
2007-06-30 $0.06B $0.01B 11.16
2007-03-31 $0.00B $0.02B 0.00
2006-12-31 $0.00B $0.01B 0.45
2006-09-30 $0.00B $0.02B 0.00
2006-06-30 $0.00B 0.00
2006-03-31 $0.00B 0.00
2005-09-30 $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.319B $0.001B
Athersys, Inc., a late stage biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused primarily on treating critical care indications neurological conditions, cardiovascular diseases, inflammatory and immune disorders, pulmonary and other conditions. The company's lead platform product is MultiStem cell therapy, an `off the shelf` allogeneic stem cell product currently in Phase 3 clinical development for treating ischemic stroke. Based on promising Phase 2 results, this program has received Fast Track and RMAT (equivalent to Breakthrough Therapy for regenerative medicine treatments) designations from the FDA, as well as similar designations in Japan. The company also has an ongoing Phase II clinical study for treating patients with acute myocardial infarction; a planned Phase II for trauma (supported by the DOD).
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.660B 8.90
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.482B 21.14
Biohaven Pharmaceutical Holding (BHVN) United States $8.764B 0.00
Emergent Biosolutions (EBS) United States $2.892B 6.98
Arcus Biosciences (RCUS) United States $2.573B 0.00
Myovant Sciences (MYOV) United Kingdom $2.051B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.021B 0.00
Zymeworks (ZYME) Canada $1.443B 0.00
Ambrx Biopharma (AMAM) United States $0.527B 0.00
SQZ Biotechnologies (SQZ) United States $0.417B 0.00
Enzo Biochem (ENZ) United States $0.172B 50.71